This database contains 59 studies, archived under the term: "nootropic agents"
Click here to filter this large number of results.
Ceraxon (citicoline) in the treatment of the mild cognitive impairment syndrome
The objective was to study efficacy and safety of ceraxon (citicoline) used perorally in dose 1000 mg daily in the treatment of cognitive disturbances in patients with amnesic type of mild cognitive impairment (MCI). Twenty patients, aged from 50 to 90 years, received ceraxon in dose 1000 mg twice a day during 90 days. The […]
Cognition and function in Alzheimer’s disease: identifying the transitions from moderate to severe disease
Background/aims: Cognitive and functional decline define the transition from moderate to severe Alzheimer’s disease (AD); however, specific relationships between deteriorating cognition and functional abilities are less well characterized. Such relationships are important in care planning and understanding patient needs. Objectives of this post hoc analysis of data from a multicenter randomized double-blind placebo-controlled study were […]
Improved visual hallucination by donepezil and occipital glucose metabolism in dementia with Lewy bodies: the Osaki-Tajiri project
Satoh, Masayuki,
Ishikawa, Hiroyasu,
Meguro, Kenichi,
Kasuya, Masashi,
Ishii, Hiroshi,
Yamaguchi, Satoshi
Deficits in the cholinergic system are pronounced in dementia with Lewy bodies (DLB) and are more severe in patients with visual hallucinations (VHs). The aim is to identify the occipital glucose metabolism patterns by positron emission tomography (PET) and the changes following donepezil treatment. 13 DLB patients with VHs were enrolled in the study. After […]
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease
Sano, M.,
Bell, K. L.,
Galasko, D.,
Galvin, J. E.,
Thomas, R. G.,
van Dyck, C. H.,
Aisen, P. S.
Background: Lowering cholesterol is associated with reduced CNS amyloid deposition and increased dietary cholesterol increases amyloid accumulation in animal studies. Epidemiologic data suggest that use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) may decrease the risk of Alzheimer disease (AD) and a single-site trial suggested possible benefit in cognition with statin treatment in AD, […]
A double-blind placebo-controlled randomized trial of Melissa officinalis oil and donepezil for the treatment of agitation in Alzheimer’s disease
Burns, Alistair,
Perry, Elaine,
Holmes, Clive,
Francis, Paul,
Morris, Julie,
Howes, Melanie-Jayne R.,
Chazot, Paul,
Lees, George,
Ballard, Clive
Background/aims: Behavioural and psychological symptoms (BPSD) are frequent in people with Alzheimer’s disease and cause considerable stress to patients and their carers. Antipsychotics have been widely used as a first-line treatment, resulting in an estimated 1,800 excess strokes and 1,600 excess deaths in the UK alone. Safe and effective alternatives are urgently needed. Based upon […]
Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer’s disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin
Alvarez, X. A.,
Cacabelos, R.,
Sampedro, C.,
Aleixandre, M.,
Linares, C.,
Granizo, E.,
Doppler, E.,
Moessler, H.
Background: cerebrolysin is a neuropeptide preparation mimicking the effects of neurotrophic factors. This subgroup analysis assessed safety and efficacy of Cerebrolysin in patients with moderate to moderately severe Alzheimer’s disease (AD) (ITT data set: N = 133; MMSE: 14-20) included in a dose-finding study (ITT data set: N = 51; MMSE: 14-25). Results of the […]